Samir R. Patel - 07 Jul 2026 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: AKTX
Reported as of: 07 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jul 2026, 06:03:07 UTC
Prior SEC filing: 18 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Abizer Gaslightwala, as Attorney-in-Fact

Key filing fact

Samir R. Patel filed Form 4 for Akari Therapeutics Plc (AKTX) on 17 Jul 2026.

Key facts

This page summarizes Samir R. Patel's Form 4 filing for Akari Therapeutics Plc (AKTX).
6 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 17 Jul 2026, 06:03.

Change

Previous filing in this sequence was filed on 18 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001702447 Primary reporting owner

Patel Samir Rashmikant

Relationship: Director, 10%+ Owner
Address: C/O AKARI THERAPEUTICS PLC, 401 EAST JACKSON STREET, SUITE 3300, TAMPA
Signature: /s/ Abizer Gaslightwala, as Attorney-in-Fact
Signature date: 17 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AKTX transaction

American Depositary Shares representing Ordinary Shares

Options Exercise

Transaction value
Shares: +1,209
Change %: +1.6%
Price: $8.00^*
Shares after: 76,976
Date: 07 Jul 2026
Ownership: PranaBio Investments LLC

AKTX transaction

American Depositary Shares representing Ordinary Shares

Options Exercise

Transaction value
Shares: +15,466
Change %: +20%
Price: $0.000400^*
Shares after: 92,442
Date: 07 Jul 2026
Ownership: PranaBio Investments LLC

AKTX transaction

American Depositary Shares representing Ordinary Shares

Options Exercise

Transaction value
Shares: +5,799
Change %: +6.3%
Price: $0.000400^*
Shares after: 98,241
Date: 07 Jul 2026
Ownership: PranaBio Investments LLC

AKTX holding

American Depositary Shares representing Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3,566
Date: 07 Jul 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AKTX transaction Derivative

Pre-Funded Warrant to purchase American Depositary Shares

Options Exercise

Transaction value
Shares: +1,209
Change %
Price: $32.00^*
Shares after: 0
Date: 07 Jul 2026
Ownership: PranaBio Investments LLC
Underlying class: American Depositary Shares representing Ordinary Shares
Underlying amount: 1,209
Exercise price: $8.00
Footnotes: F1, F2

AKTX transaction Derivative

Pre-Funded Warrant to purchase ADSs

Options Exercise

Transaction value
Shares: +15,466
Change %
Price: $16.16^*
Shares after: 0
Date: 07 Jul 2026
Ownership: PranaBio Investments LLC
Underlying class: American Depositary Shares representing Ordinary Shares
Underlying amount: 15,466
Exercise price: $0.000400
Footnotes: F2, F3, F4

AKTX transaction Derivative

Pre-Funded Warrant to purchase ADSs

Options Exercise

Transaction value
Shares: +5,799
Change %
Price: $16.16^*
Shares after: 0
Date: 07 Jul 2026
Ownership: PranaBio Investments LLC
Underlying class: American Depositary Shares representing Ordinary Shares
Underlying amount: 5,799
Exercise price: $0.000400
Footnotes: F2, F3, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Each American Depositary Share ("ADS") represents 80,000 ordinary shares with a par value of $0.000000005 per ordinary share.

Footnote F2

The pre-funded warrants remain exercisable until fully exercised.

Footnote F3

The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026.

Footnote F4

The combined purchase price per one pre-funded warrant and accompanying Series G Warrant was $16.16.

Footnote F5

On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 5,799 ADSs, at a purchase price of $16.16 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) warrants to purchase up to 5,799 ADSs.